Inactive Instrument

News Fresh Start Private Management Inc Other OTC

Equities

US35804J1025

End-of-day quote Other OTC Other stock markets
- ^USD	-

Apr. 03	BioCorRx Inc. Announces Board Resignations	CI
Apr. 01	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCorRx Reports Business Update for the First Quarter of 2024	May. 16	AQ
BioCorRx Inc. Announces Board Resignations	Apr. 03	CI
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	Apr. 03	AQ
BioCorRx Reports Business Update for 2023	Apr. 02	AQ
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	Feb. 28	AQ
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors	Feb. 08	AQ
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors	Feb. 08	CI
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President	Jan. 09	AQ
BioCorRx Inc. Announces President Changes	Jan. 05	CI
BioCorRx : Material Agreement - Form 8-K	Dec. 15	PU
BioCorRx Inc. announced that it has received $0.2 million in funding	Dec. 07	CI
BioCorRx Reports Business Update for the Third Quarter of 2023	Nov. 14	AQ
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
BioCorRx Inc. announced that it has received $0.2 million in funding	Nov. 09	CI
Biocorrx Inc. Announces Management Changes	Nov. 02	CI
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	23-08-15	AQ
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	23-08-15	CI
BioCorRx Reports Business Update for the Second Quarter of 2023	23-08-14	AQ
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Fresh Start Private Management Inc Other OTC

Equities

US35804J1025

Summary

Filters